Salacetamide is a derivative of salicylic acid. It is analgesic, anti-inflammatory and antipyretic agent.

Pyridarone is a 2-Pyridylbenzofuran derivative patented by Societe Belge de l'Azote et des Produits Chimiques du Marly S.A. as anxiolytic useful for the treatment of fear in emotions of psychogenic origin.

Serfibrate, a clofibrate derivative, is a peroxisome proliferator activated receptor-α (PPAR-α) agonist. It is a hypolipidemic agent.

Etabenzarone is an anti-inflammatory and anticoagulant agent.

Nemorubicin, a doxorubicin derivative, is a DNA-intercalator, topoisomerase and RNA synthesis inhibitor that was undergoing development with Nerviano Medical Sciences (Nerviano MS; formerly Pharmacia Italia) for the treatment of solid tumours, specifically, the loco-regional treatment of primary liver tumours (hepatocellular carcinoma). The drug is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives. It works primarily through topoisomerase I inhibition. Of note, Nemorubicin is active in cells with upregulation of the nucleotide excision repair (NER) pathway, where current therapies fail. Nemorubicin is biotransformed in the liver into cytotoxic metabolites that may further contribute to render this drug highly active against primary liver tumors or liver metastases. Clinical trials were conducted in Europe, US and China with Nemorubicin given at different dose-schedules and by different routes of administration: as single agent by systemic IV route, oral route and by intra-hepatic artery (IHA) infusion alone or in combination with cisplatin.

Bombesin (BN), a neuropeptide that originally was purified from the skin of the European frog (Bombina bombina). It has many biological effects including hormone release, stimulation of pancreatic enzyme secretion, gallbladder contraction and bronchoconstriction. Bombesin is a highly specific marker of neuroendocrine differentiation and thus a valuable tumor marker. It activates three different G-protein-coupled receptors known as BBR1, -2, and -3.

Diotyrosine I 131 is the diagnostic aid manufactured by Abbott.

S-nitrosoglutathione (GSNO) is an endogenous S-nitrosothiol that acts as a NO pool. The level of GSNO is tightly regulated by S-nitrosoglutathione reductase (GSNOR), an enzyme that degrades GSNO. GSNOR inhibitors offer a potentially promising option for the management of pre-eclampsia, a cause of maternal death and of perinatal morbidity. The GSNO treatment of traumatic brain injury improved neurobehavioral functions. GSNO can increase the expression of certain proteins at concentrations present in the normal human airway. GSNO has an important role in regulating respiratory function (breathing) and preventing inflammation in the respiratory tract, that is why this compound participated in phase I clinical trials for patients with asthma. In addition, GSNO was studied in the cystic fibrosis airway. The obtained results have shown that GSNO replacement therapy could be an effective treatment. In addition, GSNO was investigated for patients with chronic obstructive pulmonary disease.

Dibemethine is an analgesic agent.